HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Aspirin/Ibuprofen Concomitant Use Issues Need More Study – BMJ Editorial

This article was originally published in The Tan Sheet

Executive Summary

Current evidence on the negative interaction between ibuprofen and aspirin therapy "is not sufficient to make definitive recommendations for or against" concomitant use of the medications in heart patients, according to an editorial published in the Dec. 6 British Medical Journal

You may also be interested in...



Aspirin MI Prevention Benefits May Be Inhibited By Regular NSAID Use

Regular use of non-steroidal anti-inflammatory drugs may lessen the benefits of aspirin in reducing risk of myocardial infarction, a study recently published in Circulation says

Ibuprofen, Preventive Aspirin Therapy May Have “Deleterious” Effect – Study

Ibuprofen combined with aspirin therapy for secondary prevention of cardiovascular disease "may be deleterious," researchers say in the Feb. 15 The Lancet

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS129310

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel